Head to Head Comparison: Maravai LifeSciences (MRVI) & Its Peers

Maravai LifeSciences (NASDAQ:MRVI) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it weigh in compared to its rivals? We will compare Maravai LifeSciences to similar businesses based on the strength of its profitability, institutional ownership, dividends, valuation, earnings, analyst recommendations and risk.

Profitability

This table compares Maravai LifeSciences and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-30.83%	-12.44%	-6.66%
Maravai LifeSciences Competitors	-538.84%	77.01%	-13.58%

Valuation and Earnings

This table compares Maravai LifeSciences and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Maravai LifeSciences	$185.74 million	-$130.77 million	-17.35
Maravai LifeSciences Competitors	$2.26 billion	$55.88 billion	-7.67

Maravai LifeSciences’ rivals have higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Maravai LifeSciences has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Maravai LifeSciences’ rivals have a beta of 0.94, indicating that their average share price is 6% less volatile than the S&P 500.

Institutional & Insider Ownership

50.2% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 53.5% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 15.0% of shares of all “Life Sciences Tools & Services” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Maravai LifeSciences and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1	1	3	1	2.67
Maravai LifeSciences Competitors	957	3188	5525	178	2.50

Maravai LifeSciences presently has a consensus target price of $8.10, suggesting a potential upside of 8.58%. As a group, “Life Sciences Tools & Services” companies have a potential upside of 1.15%. Given Maravai LifeSciences’ stronger consensus rating and higher possible upside, analysts plainly believe Maravai LifeSciences is more favorable than its rivals.

Summary

Maravai LifeSciences rivals beat Maravai LifeSciences on 8 of the 13 factors compared.

About Maravai LifeSciences

Maravai LifeSciences provides products and services used by biotechnology and pharmaceutical companies in the development and production of therapeutics, vaccines, and other biologic products. Its offerings include specialized nucleic acid materials and analytical testing services that support research, manufacturing, and quality control. Through TriLink BioTechnologies, the company supplies modified nucleotides, custom RNA and DNA, and related materials used in applications such as messenger RNA research and production.